SNSE · Sensei Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $11.33M | $13.04M | $18.77M | $19.80M | $7.53M |
| Total Operating Expenses | $22.29M | $32.61M | $37.06M | $50.19M | $19.45M |
| D&A | $122.0K | $551.0K | $571.0K | $614.0K | $209.0K |
| Operating Income | ($22.29M) | ($32.61M) | ($37.06M) | ($50.19M) | ($19.45M) |
| Interest Expense | $32.0K | $90.0K | $144.0K | $219.0K | $1.69M |
| Income Tax | $0 | - | - | - | - |
| Net Income | ($21.09M) | ($30.16M) | ($34.10M) | ($48.59M) | ($20.10M) |
| EPS - Basic | ($16.72) | ($24.00) | ($24.40) | ($26.60) | - |
| EPS - Diluted | ($16.72) | ($24.00) | ($24.40) | ($26.60) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8.67M | $9.99M | $13.01M | $17.80M | $7.16M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $689.0K | $573.0K | - | - | - |
| Current Assets | $21.51M | $41.93M | $67.25M | $108.59M | $148.54M |
| Total Assets | $22.90M | $45.36M | $74.37M | $118.38M | $153.22M |
| Current Liabilities | $4.25M | $5.45M | $5.64M | $9.07M | $4.89M |
| Long-term Debt | - | - | - | - | $567.0K |
| Total Liabilities | $4.31M | $6.97M | $9.48M | $14.97M | $6.71M |
| Stockholders' Equity | $18.59M | $38.39M | $64.89M | $103.41M | $146.51M |
| Retained Earnings | ($283.14M) | ($262.05M) | ($231.90M) | ($197.79M) | ($149.21M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($20.45M) | ($24.67M) | ($32.02M) | ($39.03M) | ($17.70M) |
| Investing Cash Flow | $19.77M | $22.44M | $38.41M | $49.95M | ($1.40M) |
| Financing Cash Flow | ($645.0K) | ($787.0K) | ($11.17M) | ($287.0K) | $35.45M |
| CapEx | $16.0K | $146.0K | $180.0K | $321.0K | $1.21M |
| Free Cash Flow | ($20.47M) | ($24.82M) | ($32.20M) | ($39.35M) | ($18.91M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.97 | 0.82 | 0.94 | 0.81 | 0.94 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -92.1% | -66.5% | -45.9% | -41.0% | -13.1% |
| Return on equity | -113.4% | -78.6% | -52.5% | -47.0% | -13.7% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 |
| Quick ratio | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 |
| Cash ratio | 2.04 | 1.83 | 2.31 | 1.96 | 1.46 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -696.5x | -362.4x | -257.4x | -229.2x | -11.5x |
| Equity multiplier | 1.23 | 1.18 | 1.15 | 1.14 | 1.05 |
| Liabilities / Assets | 0.19 | 0.15 | 0.13 | 0.13 | 0.04 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.7x | 6.4x | 6.0x | 8.0x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 31.7% | 12.0% | 26.1% | -158.0% | - |
| Net income growth (YoY) | 30.1% | 11.6% | 29.8% | -141.7% | - |
| EPS growth (YoY) | 30.3% | 1.6% | 8.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 17.5% | 22.9% | 18.2% | -108.1% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -51.6% | -40.8% | -37.2% | -29.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sensei Biotherapeutics against the 5 most active filers in the same SIC group.